Public Service Enterprise Group Stock News

Pharma Equity Group's subsidiary, Reponex Pharmaceuticals A/S, receives regulatory approval to initiate pivotal clinical trial with RNX-011 for life-threatening peritonitis This company announcement replaces company announcement no. 10 published on 1 September 2025.

Pharma Equity Group's subsidiary, Reponex Pharmaceuticals A/S, receives regulatory approval to initiate pivotal clinical trial with RNX-011 for life-threatening peritonitis Copenhagen, September 01, 2025 Company Announcement No. 10 Reponex Pharmaceuticals A/S (Reponex), a subsidiary of Pharma Equity Group A/S (NASDAQ: PEG), today announced that it has received regulatory approval to initiate a ...

I maintain my strong buy rating on PEG, driven by surging data center demand and a robust 2Q25 earnings beat. PEG's large-load inquiry pipeline soared to 9.4 GW, with ~90% tied to data centers, underscoring a powerful multi-year growth runway. Higher PJM auction clearing prices and nuclear fleet optimization initiatives significantly boost PEG's earnings visibility and de-risk future cash flows.

The world is having a “nuclear renaissance,” according to Morgan Stanley, and the opportunity for investors is ample.

Public Service (PEG) Q2 EPS Jumps 22%

Public Service Enterprise Group Incorporated (NYSE:PEG ) Q2 2025 Earnings Conference Call August 5, 2025 11:00 AM ET Company Participants Carlotta N. Chan - Vice President of Investor Relations Daniel J.

$1.17 PER SHARE NET INCOME $0.77 PER SHARE NON-GAAP OPERATING EARNINGS Maintains 2025 Non-GAAP Operating Earnings Guidance of $3.94 - $4.06 Per Share NEWARK, N.J., Aug. 5, 2025 /PRNewswire/ -- Public Service Enterprise Group (NYSE: PEG) reported the following results for the second quarter and six months ended June 30, 2025: PSEG Consolidated (unaudited)Second Quarter Comparative Results Income...

NEWARK, N.J. , Aug. 4, 2025 /PRNewswire/ -- New Jersey customers are saving money and energy through the PSE&G energy efficiency programs.